These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 32401825)

  • 21. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers.
    Kim KJ; Lee KS; Cho HJ; Kim YH; Yang HK; Kim WH; Kang GH
    Hum Pathol; 2014 Feb; 45(2):285-93. PubMed ID: 24331841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
    Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
    BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
    Miglietta F; Ragazzi M; Fernandes B; Griguolo G; Massa D; Girardi F; Bottosso M; Bisagni A; Zarrilli G; Porra F; Iannaccone D; Dore L; Gaudio M; Santandrea G; Fassan M; Lo Mele M; De Sanctis R; Zambelli A; Bisagni G; Guarneri V; Dieci MV
    Clin Cancer Res; 2023 Sep; 29(17):3429-3437. PubMed ID: 37417941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
    Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
    Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
    Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
    García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
    Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
    Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.
    Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G
    Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.
    Rustamadji P; Wiyarta E; Pramono M; Maulanisa SC
    Asian Pac J Cancer Prev; 2024 May; 25(5):1607-1613. PubMed ID: 38809632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
    Jørgensen N; Hviid TVF; Nielsen LB; Sønderstrup IMH; Eriksen JO; Ejlertsen B; Gerdes AM; Kruse TA; Thomassen M; Jensen MB; Lænkholm AV
    Br J Cancer; 2021 Nov; 125(10):1388-1398. PubMed ID: 34365471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
    Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
    BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.